Virtu Financial LLC Purchases Shares of 18,419 CorMedix Inc. (NASDAQ:CRMD)

Virtu Financial LLC acquired a new position in shares of CorMedix Inc. (NASDAQ:CRMD) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,419 shares of the company’s stock, valued at approximately $149,000.

Several other hedge funds also recently modified their holdings of the company. FMR LLC boosted its holdings in shares of CorMedix by 54.3% in the 3rd quarter. FMR LLC now owns 4,618 shares of the company’s stock worth $37,000 after acquiring an additional 1,625 shares in the last quarter. AlphaMark Advisors LLC raised its position in CorMedix by 16.7% in the 4th quarter. AlphaMark Advisors LLC now owns 14,000 shares of the company’s stock valued at $113,000 after purchasing an additional 2,000 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its stake in CorMedix by 2.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 149,834 shares of the company’s stock worth $1,214,000 after purchasing an additional 3,221 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of CorMedix by 8.6% during the fourth quarter. Rhumbline Advisers now owns 75,747 shares of the company’s stock worth $614,000 after purchasing an additional 6,028 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of CorMedix by 130.3% in the third quarter. BNP Paribas Financial Markets now owns 11,950 shares of the company’s stock valued at $97,000 after buying an additional 6,761 shares in the last quarter. Institutional investors and hedge funds own 34.18% of the company’s stock.

Wall Street Analysts Forecast Growth

CRMD has been the topic of several research reports. Needham & Company LLC reduced their price target on shares of CorMedix from $18.00 to $12.00 and set a “buy” rating on the stock in a research report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and set a $12.00 target price on shares of CorMedix in a research report on Wednesday. Leerink Partnrs raised shares of CorMedix to a “strong-buy” rating in a report on Friday, March 7th. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of CorMedix in a report on Tuesday, March 25th. Finally, Leerink Partners began coverage on CorMedix in a research report on Friday, March 7th. They issued an “outperform” rating and a $18.00 price objective on the stock. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $15.14.

CorMedix Stock Up 0.4 %

CRMD stock opened at $6.74 on Friday. The business’s fifty day moving average is $10.43 and its 200-day moving average is $9.91. The company has a market cap of $408.96 million, a P/E ratio of -8.32 and a beta of 1.53. CorMedix Inc. has a twelve month low of $3.61 and a twelve month high of $13.85.

CorMedix (NASDAQ:CRMD) last posted its earnings results on Tuesday, March 25th. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.05. The company had revenue of $30.00 million for the quarter, compared to analyst estimates of $27.46 million. The business’s quarterly revenue was up 29900.0% on a year-over-year basis. Research analysts anticipate that CorMedix Inc. will post -0.32 earnings per share for the current fiscal year.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.